Based on its preclinical activity in in-vitro models without causing hyperglycemia, a phase 1 trial (PIKASSO-01) is being conducted in PIK3CA H1047R-mutant advanced breast cancer and other solid tumors [147]. The gene discussed is PIK3CA; the disease is breast carcinoma.